|
1
|
Dauer W and Przedborski S: Parkinson’s
disease: mechanisms and models. Neuron. 39:889–909. 2003.
|
|
2
|
Arora A and Fletcher P: Problem based
review: a patient with Parkinson’s disease. Acute Med. 12:246–250.
2013.
|
|
3
|
Olanow CW and Tatton WG: Etiology and
pathogenesis of Parkinson’s disease. Annu Rev Neurosci. 22:123–144.
1999.
|
|
4
|
Wirdefeldt K, Adami HO, Cole P,
Trichopoulos D and Mandel J: Epidemiology and etiology of
Parkinson’s disease: a review of the evidence. Eur J Epidemiol.
26(Suppl 1): S1–S58. 2011.
|
|
5
|
Vaglini F, Viaggi C, Piro V, et al:
Acetaldehyde and parkinsonism: role of CYP450 2E1. Front Behav
Neurosci. 7:712013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lill CM, Roehr JT, McQueen MB, et al:
Comprehensive research synopsis and systematic meta-analyses in
Parkinson’s disease genetics: The PDGene database. PLoS Genet.
8:e10025482012.PubMed/NCBI
|
|
7
|
McInerney-Leo A, Hadley DW, Gwinn-Hardy K
and Hardy J: Genetic testing in Parkinson’s disease. Mov Disord.
20:1–10. 2005.
|
|
8
|
Bekris LM, Mata IF and Zabetian CP: The
genetics of Parkinson disease. J Geriatr Psychiatry Neurol.
23:228–242. 2010. View Article : Google Scholar
|
|
9
|
Dias V, Junn E and Mouradian MM: The role
of oxidative stress in Parkinson’s disease. J Parkinsons Dis.
3:461–491. 2013.
|
|
10
|
van Muiswinkel FL, de Vos RA, Bol JG, et
al: Expression of NAD(P)H:quinone oxidoreductase in the normal and
Parkinsonian substantia nigra. Neurobiol Aging. 25:1253–1262.
2004.PubMed/NCBI
|
|
11
|
Kamoun M, Chelbi H, Houman MH, Lacheb J
and Hamzaoui K: Tumor necrosis factor gene polymorphisms in
Tunisian patients with Behcet’s disease. Hum Immunol. 68:201–205.
2007.PubMed/NCBI
|
|
12
|
Dobbs RJ, Charlett A, Purkiss AG, Dobbs
SM, Weller C and Peterson DW: Association of circulating TNF-alpha
and IL-6 with ageing and parkinsonism. Acta Neurol Scand.
100:34–41. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Harada S, Fujii C, Hayashi A and Ohkoshi
N: An association between idiopathic Parkinson’s disease and
polymorphisms of phase II detoxification enzymes: glutathione
S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem
Biophys Res Commun. 288:887–892. 2001.
|
|
14
|
Shao M, Liu Z, Tao E and Chen B:
Polymorphism of MAO-B gene and NAD(P)H: quinone oxidoreductase gene
in Parkinson’s disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi.
18:122–124. 2001.(In Chinese).
|
|
15
|
Jiang XH, Yang H, Yang JF, Wang HT, Xu QY
and Chen B: A study on the relationship between polymorphism of
human NAD(P)H: quinone oxidoreductase and Parkinson’s disease in
Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 21:120–123. 2004.(In
Chinese).
|
|
16
|
Okada S, Farin FM, Stapleton P, et al: No
associations between Parkinson’s disease and polymorphisms of the
quinone oxidoreductase (NQO1, NQO2) genes. Neurosci Lett.
375:178–180. 2005.
|
|
17
|
Shao M, Liu ZL, Tao EX and Chen B:
Correlation between the genetic polymorphism of dopamine metabolic
enzymes and the genetic susceptibility of Parkinson’s disease. Chin
J Gerontol. 25:743–745. 2005.
|
|
18
|
Xu H, Du W, Sun Z, et al: Genetic analysis
of P2X7 C489T and NQO1 C609T polymorphisms and susceptibility of
primary Parkinson’s disease. Chin J Exp Surg. 24:1310–1312.
2007.
|
|
19
|
Punia S, Das M, Behari M, et al: Leads
from xenobiotic metabolism genes for Parkinson’s disease among
north Indians. Pharmacogenet Genomics. 21:790–797. 2011.
|
|
20
|
Fong CS, Wu RM, Shieh JC, et al: Pesticide
exposure on southwestern Taiwanese with MnSOD and NQO1
polymorphisms is associated with increased risk of Parkinson’s
disease. Clin Chim Acta. 378:136–141. 2007.PubMed/NCBI
|
|
21
|
Krüger R, Hardt C, Tschentscher F, et al:
Genetic analysis of immunomodulating factors in sporadic
Parkinson’s disease. J Neural Transm. 107:553–562. 2000.PubMed/NCBI
|
|
22
|
Ross OA, O’Neill C, Rea IM, et al:
Functional promoter region polymorphism of the proinflammatory
chemokine IL-8 gene associates with Parkinson’s disease in the
Irish. Hum Immunol. 65:340–346. 2004.PubMed/NCBI
|
|
23
|
Wahner AD, Sinsheimer JS, Bronstein JM and
Ritz B: Inflammatory cytokine gene polymorphisms and increased risk
of Parkinson disease. Arch Neurol. 64:836–840. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu YR, Feng IH, Lyu RK, et al: Tumor
necrosis factor-alpha promoter polymorphism is associated with the
risk of Parkinson’s disease. Am J Med Genet B Neuropsychiatr Genet.
144B:300–304. 2007.
|
|
25
|
Bialecka M, Klodowska-Duda G, Kurzawski M,
et al: Interleukin-10 (IL10) and tumor necrosis factor alpha (TNF)
gene polymorphisms in Parkinson’s disease patients. Parkinsonism
Relat Disord. 14:636–640. 2008.
|
|
26
|
Du WD, Tang XF, Tang HY, et al: Tumor
necrosis factor alpha (TNFα) rs1800629 and lymphotoxin alpha (LTA)
rs909253 might not be potential susceptibility locus leading to
Chinese sporadic Parkinson’s disease. Chin J Dis Control Prev.
13:33–38. 2009.
|
|
27
|
Pascale E, Passarelli E, Purcaro C, et al:
Lack of association between IL-1β, TNF-α, and IL-10 gene
polymorphisms and sporadic Parkinson’s disease in an Italian
cohort. Acta Neurol Scand. 124:176–181. 2011.
|
|
28
|
Nishimura M, Mizuta I, Mizuta E, et al:
Tumor necrosis factor gene polymorphisms in patients with sporadic
Parkinson’s disease. Neurosci Lett. 311:1–4. 2001.
|
|
29
|
Infante J, García-Gorostiaga I,
Sánchez-Juan P, et al: Inflammation-related genes and the risk of
Parkinson’s disease: a multilocus approach. Eur J Neurol.
15:431–433. 2008.PubMed/NCBI
|
|
30
|
Zintzaras E and Lau J: Trends in
meta-analysis of genetic association studies. J Hum Genet. 53:1–9.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu X, Wang Y, Wang L, et al: Meta-analyses
of 8 polymorphisms associated with the risk of the Alzheimer’s
disease. PloS One. 8:e731292013.
|
|
32
|
Yu X, Huang Y, Li C, Yang H, Lu C and Duan
S: Positive association between lymphotoxin-alpha variation
rs909253 and cancer risk: a meta-analysis based on 36 case-control
studies. Tumour Biol. 35:1973–1983. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ye H, Li X, Wang L, et al: Genetic
associations with coronary heart disease: meta-analyses of 12
candidate genetic variants. Gene. 531:71–77. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tang L, Wang L, Liao Q, et al: Genetic
associations with diabetes: meta-analyses of 10 candidate
polymorphisms. PloS One. 8:e703012013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Excoffier L, Laval G and Schneider S:
Arlequin (version 3.0): an integrated software package for
population genetics data analysis. Evol Bioinform Online. 1:47–50.
2007.
|
|
36
|
Gibson E, Fenster A and Ward AD: The
impact of registration accuracy on imaging validation study design:
A novel statistical power calculation. Med Image Anal. 17:805–815.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Coory MD: Comment on: Heterogeneity in
meta-analysis should be expected and appropriately quantified. Int
J Epidemiol. 39:932–933. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kawalec P, Mikrut A, Wiśniewska N and Pilc
A: The effectiveness of tofacitinib, a novel Janus kinase
inhibitor, in the treatment of rheumatoid arthritis: a systematic
review and meta-analysis. Clin Rheumatol. 32:1415–1424. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Higuchi T, Seki N, Kamizono S, et al:
Polymorphism of the 5′-flanking region of the human tumor necrosis
factor (TNF)-alpha gene in Japanese. Tissue Antigens. 51:605–612.
1998.
|
|
40
|
Hughes AJ, Daniel SE, Kilford L and Lees
AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s
disease: a clinico-pathological study of 100 cases. J Neurol
Neurosurg Psychiatry. 55:181–184. 1992.
|
